Regional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study.
Antibiotics
Fluoroquinolones
Utilization
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
03 Aug 2021
03 Aug 2021
Historique:
received:
06
05
2021
accepted:
21
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Serious adverse effects of fluoroquinolone antibiotics have been described for more than decade. Recently, several drug regulatory agencies have advised restricting their use in milder infections for which other treatments are available, given the potential for disabling and possibly persistent side effects. We aimed to describe variations in fluoroquinolone use for initial treatment of urinary tract infection (UTI), acute bacterial sinusitis (ABS), and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the outpatient setting across Canada. Using administrative health data from six provinces, we identified ambulatory visits with a diagnosis of uncomplicated UTI, uncomplicated AECOPD or ABS. Antibiotic exposure was determined by the first antibiotic dispensed within 5 days of the visit. We identified 4,303,144 uncomplicated UTI events among 2,170,027 women; the proportion of events treated with fluoroquinolones, mostly ciprofloxacin, varied across provinces, ranging from 18.6% (Saskatchewan) to 51.6% (Alberta). Among 3,467,678 ABS events (2,087,934 patients), between 2.2% (Nova Scotia) and 11.2% (Ontario) were dispensed a fluoroquinolone. For 1,319,128 AECOPD events among 598,347 patients, fluoroquinolones, mostly levofloxacin and moxifloxacin, ranged from 5.8% (Nova Scotia) to 35.6% (Ontario). The proportion of uncomplicated UTI and ABS events treated with fluoroquinolones declined over time, whereas it remained relatively stable for AECOPD. Fluoroquinolones were commonly used as first-line therapies for uncomplicated UTI and AECOPD. However, their use varied widely across provinces. Drug insurance formulary criteria and enforcement may be a key to facilitating better antibiotic stewardship and limiting potentially inappropriate first-line use of fluoroquinolones.
Sections du résumé
BACKGROUND
BACKGROUND
Serious adverse effects of fluoroquinolone antibiotics have been described for more than decade. Recently, several drug regulatory agencies have advised restricting their use in milder infections for which other treatments are available, given the potential for disabling and possibly persistent side effects. We aimed to describe variations in fluoroquinolone use for initial treatment of urinary tract infection (UTI), acute bacterial sinusitis (ABS), and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the outpatient setting across Canada.
METHODS
METHODS
Using administrative health data from six provinces, we identified ambulatory visits with a diagnosis of uncomplicated UTI, uncomplicated AECOPD or ABS. Antibiotic exposure was determined by the first antibiotic dispensed within 5 days of the visit.
RESULTS
RESULTS
We identified 4,303,144 uncomplicated UTI events among 2,170,027 women; the proportion of events treated with fluoroquinolones, mostly ciprofloxacin, varied across provinces, ranging from 18.6% (Saskatchewan) to 51.6% (Alberta). Among 3,467,678 ABS events (2,087,934 patients), between 2.2% (Nova Scotia) and 11.2% (Ontario) were dispensed a fluoroquinolone. For 1,319,128 AECOPD events among 598,347 patients, fluoroquinolones, mostly levofloxacin and moxifloxacin, ranged from 5.8% (Nova Scotia) to 35.6% (Ontario). The proportion of uncomplicated UTI and ABS events treated with fluoroquinolones declined over time, whereas it remained relatively stable for AECOPD.
CONCLUSIONS
CONCLUSIONS
Fluoroquinolones were commonly used as first-line therapies for uncomplicated UTI and AECOPD. However, their use varied widely across provinces. Drug insurance formulary criteria and enforcement may be a key to facilitating better antibiotic stewardship and limiting potentially inappropriate first-line use of fluoroquinolones.
Identifiants
pubmed: 34344348
doi: 10.1186/s12879-021-06467-z
pii: 10.1186/s12879-021-06467-z
pmc: PMC8330086
doi:
Substances chimiques
Fluoroquinolones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
733Informations de copyright
© 2021. The Author(s).
Références
Lancet Infect Dis. 2014 Aug;14(8):742-750
pubmed: 25022435
Am Fam Physician. 2002 Feb 1;65(3):455-64
pubmed: 11858629
Can Fam Physician. 2014 Mar;60(3):227-34
pubmed: 24627376
Open Med. 2012 Oct 30;6(4):e134-40
pubmed: 23687528
JAMA Intern Med. 2016 Nov 1;176(11):1639-1648
pubmed: 27653796
BMJ. 2018 Mar 8;360:k678
pubmed: 29519881
Neurology. 2014 Sep 30;83(14):1261-3
pubmed: 25150290
PLoS One. 2017 Jul 27;12(7):e0181957
pubmed: 28750020
Eur J Clin Pharmacol. 2007 May;63(5):499-503
pubmed: 17334751
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
PLoS One. 2014 Sep 09;9(9):e107515
pubmed: 25203557
JAMA. 2012 Apr 4;307(13):1414-9
pubmed: 22474205
Eur J Intern Med. 2020 May;75:60-70
pubmed: 31983604
Clin Microbiol Infect. 2020 May;26(5):613-618
pubmed: 31655215
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28348151
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
BMJ Open. 2015 Nov 18;5(11):e010077
pubmed: 26582407
Pharmacoepidemiol Drug Saf. 2020 Jan;29 Suppl 1:103-107
pubmed: 31814201
N Engl J Med. 2016 Sep 8;375(10):962-70
pubmed: 27602668
CMAJ Open. 2017 Dec 21;5(4):E878-E885
pubmed: 29273579
Laryngoscope. 2010 May;120(5):1057-62
pubmed: 20422704
BMC Infect Dis. 2015 Nov 25;15:545
pubmed: 26607324
Int J Chron Obstruct Pulmon Dis. 2019 Dec 18;14:2939-2946
pubmed: 31908442
J Otolaryngol Head Neck Surg. 2011 May;40 Suppl 2:S99-193
pubmed: 21658337
Can Respir J. 2003 Jul-Aug;10(5):248-58
pubmed: 12945001
Am J Med. 2007 Oct;120(10):893-900
pubmed: 17904461
Can J Infect Dis Med Microbiol. 2011 Spring;22(1):19-24
pubmed: 22379484
CMAJ. 2008 Mar 25;178(7):845-54
pubmed: 18362380
Can J Infect Dis Med Microbiol. 2014 Mar;25(2):99-102
pubmed: 24855478
J Antimicrob Chemother. 2013 May;68 Suppl 1:i23-9
pubmed: 23587775